KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EBIT: 2014-2024

Historic EBIT for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Dec 2024 value amounting to -$4.7 million.

  • Aurinia Pharmaceuticals' EBIT rose 153.19% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year increase of 314.14%. This contributed to the annual value of -$4.7 million for FY2024, which is 94.89% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported EBIT of -$4.7 million as of FY2024, which was up 94.89% from -$91.7 million recorded in FY2023.
  • In the past 5 years, Aurinia Pharmaceuticals' EBIT registered a high of -$4.7 million during FY2024, and its lowest value of -$180.7 million during FY2021.
  • Moreover, its 3-year median value for EBIT was -$91.7 million (2023), whereas its average is -$69.3 million.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' EBIT plummeted by 73.30% in 2021, and later skyrocketed by 94.89% in 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' EBIT (Yearly) stood at -$104.3 million in 2020, then tumbled by 73.30% to -$180.7 million in 2021, then skyrocketed by 38.32% to -$111.5 million in 2022, then rose by 17.74% to -$91.7 million in 2023, then spiked by 94.89% to -$4.7 million in 2024.